Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

Những quyển sách tương tự

• Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
  Bằng: Strand, Vibeke, et al.
  Được phát hành: (2018)
• Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
  Bằng: Genovese, Mark C., et al.
  Được phát hành: (2020)
• Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
  Bằng: Burmester, Gerd R, et al.
  Được phát hành: (2019)
• Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
  Bằng: Fleischmann, Roy, et al.
  Được phát hành: (2017)
• Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
  Bằng: Gabay, Cem, et al.
  Được phát hành: (2020)